Research programme: inhibitory small molecule therapeutics - Mitsubishi Tanabe Pharma Corporation
Latest Information Update: 25 May 2010
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 25 May 2010 Discontinued for Undefined indication in Japan (unspecified route)
- 11 Oct 2007 Research in Undefined indication in Japan (unspecified route)